- 51-200 Employees
- Based in Heidelberg, Germany
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell bispecific antibody (TandAb) that completed Phase I clinical trial for the treatment of various CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma.
Most Recent Responsibility Report
2022 Sustainability Report
Our service enables potential investors to review the most recent and archived Affimed NV Sustainability Report, Affimed NV Corporate Social Responsibility Report, Affimed NV CSR Report, Affimed NV Corporate Responsibility, Affimed NV CR Report, Affimed NV Citizenship Report, Affimed NV ESG Report, and Affimed NV Environmental Report online.